Controlling exposure to antibiotics is important for stewardship programs, and even more so in neonatal intensive care units.
The quest to reduce antibiotic resistance and to utilize antibiotic stewardship has been one of the biggest drives in medicine over the past decade. Research into the effect of exposure to antibiotics early in life has also led to a push to reduce the use in newborns and particularly in the neonatal intensive care unit. A report in Pediatrics offers the results of a comprehensive quality improvement run in a level 4 neonatal intensive care unit that had the goal of decreasing the antibiotic use rate by 20%.1
The investigators ran that initiative within the context a multicenter learning collaborative that was focused on reducing the unnecessary use of antibiotics. The strategies for improvement addressed the gaps seen in the core elements of antibiotic stewardship programs. Outcomes measured included the antibiotic use rate and the percentage of infants who were discharged without any exposure to antibiotics.
At the baseline of the quality initiative, the antibiotic use rate was 27.6% and it decreased to 15.5%, which was a 43% reduction in antibiotic use. The reduction was additionally maintained for >18 months. The investigators said that changes that had the biggest effect on this decrease included a 36-hour hard stop for antibiotics, a novel guideline for early-onset sepsis evaluation among infants <35 weeks, implementing a sepsis risk calculator, and adopting a 36-hour rule-out period for sepsis evaluation.
Continue reading this article on Contemporary Pediatrics.
FDA Expands Tenofovir Alafenamide Indication to Treat HBV in Patients as Young as 6
March 28th 2024Tenofovir alafenamide was originally approved by the FDA in 2016 to treat adults with chronic HBV infection with compensated liver disease and in 2022 to treat pediatric patients aged 12 years and older.
Paxlovid EUA Revision Narrows Emergency Use to Pediatric Patients
January 29th 2024The FDA states the revision to the emergency use authorization (EUA) is the next phase in the transition from the use of EUA-labeled nirmatrelvir and ritonavir to the use of NDA-labeled nirmatrelvir and ritonavir.